Section Reviews Biologicals & Lmmunologicals: The interferons in haematologic malignancies

References

• ISAACS A, LINDENMANN J: Virus interference I: TheInterferon. Proc. R. Soc. Lond. 1131oli (1957) 147:258–267.
   PubMed Web of Science ®Google Scholar
• ZOON KC: Human interferons: Structure and function.In: Interferon 9. Gresser (Ed.), New York, Academic Press (1987):1–12.
   Google Scholar
• TANIGUCHI T, SAKAI M, FIJB-KURIYAMA Y, ET AL.: Con-struction and identification of a bacterial plasmicl con-taining the human fibroblast interferon gene sequence. Proc Jpn. Acad. (1979) 55:464–469.
   Google Scholar
• SHOWS TB, SAKAGUCHI AY, NAYLOR SL, ET AL.: Cluster-ings of leukocyte and fibroblast interferon clones on human chromosome 9. Science (1982) 218:373–376.
   Google Scholar
• KLIMPEL GR, INFANTE AJ, PATTERSON J, HESS CB, ASUN-CION M: Virus-induced interferon a/B (EFN-a/) produc-tion by T-cells and by 'MI and Th2 helper T-cell clones: A study of the immunoregulatory actions of IFN-gamma versus LEN-a/13 on functions of different T-cell popula-tions. Cell. Immunol. (1.990) 128:603–618.
   Google Scholar
• EPSTEIN LB, GUPTA S: Human T-lymphocyte subsetproduction of immune (gamma) interferon. J. Clin. Immunol. (1981) 1:186–194.
   PubMed Web of Science ®Google Scholar
• O'MALLAY JA, NUSSBAUM-BLUMENSON A, SHEEDY D, ETAL.: Identification of the T-cell subset that produces human gamma-Interferon.]. Immunol. (1982) 128:2522–2526.
   Google Scholar
• KASHARA T, HOOKS JJ, DOUGHERTY SF, ET AL.: Inter-leukin-2-mediated immune interferon (IFN-gamma) production by human T-cells and T-cell subsets.]. Im-munol. (1983) 130:1784–1789.
   Google Scholar
• NUGENT KM, GLAZIER J, MONICK MM, ET AL.: Stimulated human alveolar macrophages secrete interferon. Am. Rev. Respir. Dis. (1985) 131:714–718.
   PubMed Web of Science ®Google Scholar
• KOHASE M, LAY LT, TAMM I, ET AL.: A cytokine network in human diploid fibroblasts: Interactions of beta inter-ferons, tumour necrosis factor, platelet-derived growth factor and interleukin-1. MoL Cell Biol. (1987) 7:273–280.
   Google Scholar
• VANDAMME J, DELAEY M, OPDENAICKER G, ET AL.: Ho-mogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature (1985) 314:266–268.
   Google Scholar
• BRANCA AA, BAGLIONI C: Evidence that types I and IIinterferons have different receptors. Nature (1981) 294: 768–770.
   PubMed Web of Science ®Google Scholar
• AGUET M, DEMBIC Z, MERLIN G: Molecular cloning andexpression of the human interferon-gamma receptor. Cell (1988) 55: 273–280.
   PubMed Web of Science ®Google Scholar
• HANNIGAN GE, FISH EN, WILLIAMS BRG: Modulation ofhuman interferon-a receptor expression by human interferon-gamma. J. Biol. Chem. (1984) 259:8084–8086.
   PubMed Web of Science ®Google Scholar
• FORTI RL, MITCHELL WM, HUBBARD WC, ET AL.: Pleiot-ropic activities of human interferorts are mediated by multiple media response pathways. Proc. Natl. Acad. Sci. USA (1984) 81:170–174.
   Google Scholar
• LEVY DE, KESSLER DS, PINE R, ET AL.: Cytoplasmicactivation of ISGF3, the positive regulator of interferon a-stimulated transcription, reconstituted in vitro. Genes Dev. (1989) 3:1362–1371.
   Google Scholar
• LARNER AC, CHAUDHURI A, DARNELL JE JR.: Transcrip-tional induction by interferon. New protein(s) deter-mine the extent and length of the induction. J. Biol. Chem. (1986) 261:453–459.
   Google Scholar
• ISRAEL A, KIMURA A, FOURNIER A, ET AL.: Interferonresponse potentiates activity of an enhancer in the promoter region of a mouse H-2 gene. Nature (1986) 322:743–746.
   Google Scholar
• TROWN PW, WILLS RJ, KAMM JJ: The preclinical develop-ment of Roferon-A. Cancer (1986) 57:1648–1656.
   PubMed Web of Science ®Google Scholar
• TROTTA PP: Preclinical biology of alpha interferons. Semin. Oncol. (1986) 3\(Suppl. 2):3–12.
   Google Scholar
• WELLS V, MALLUCI L: Expression of the 2-5A system during the cell cycle. Exp. Cell Res. (1985) 159:27–36.
   PubMed Web of Science ®Google Scholar
• TAMM I, UN SL, PFEFFER LM, ET AL.: Interferons a and beta as cellular regulatory models. In: Interferon 9. Gresser I (Ed.), New York, Academic Press (1987):13–74.
   Google Scholar
• ICESSLER DS, PINE R, PFEFFER LM, ET AL.: Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J. (1988) 7:3779–3783.
   Google Scholar
• CLEMENS MJ: Molecular mechanisms of interferon ac-tion. Br. J. COn. Pract. (1988) SuppL 62:5–12.
   Google Scholar
• INGLOT AD, OLESZAC E, KISIELOW B: Antagonism in action between mouse or human interferon and plate-let growth factor. Arch. Vim!. (1980) 63:291–296.
   PubMed Web of Science ®Google Scholar
• SUGARMAN BJ, AGGARWAL BB, HASS PE, ET AL.: Recom-binant human tumour necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science (1985) 230:943–945.
   Google Scholar
• PFEFFER LM, DONNER DB, TAMM I: Interferon-alpha down-regulates insulin receptors in lymphoblastoid (Daudi) cells. Relationship to inhibition of cell prolif-eration.]. Biol. Chem. (1987) 262:3665–3670.
   PubMed Web of Science ®Google Scholar
• HELSOP HE, BIANCHI ACM, CORDINGLEY FT, TURNER M,DE MEL CP, HOFFBRAND AV, BRENNER MK: Effects of Interferon a on autocrine growth factor loops in B-Iym-phoproliferative disorders. J. Exp. Med. (1990) 172:1729–1734.
   PubMedGoogle Scholar
• DIAZ MO, ZIEMEN S, LEBEAU MM, ET AL.: Homozyousdeletion of the a- and betas- interferon genes in human leukaemia and derived cell lines. Proc. Natl. Acad. Sci. USA (1988) 85:5259–5263.
   Google Scholar
• SAMUEL CE: The elF-2a protein kinases, regulators oftranslation in eukaryotes from yeasts to humans./ Biol. Chem. (1993) 368:7603–7606.
   Google Scholar
• MEURS EF, GALABRU J, BARBER GN, KATZE MG, HOVA-NESSIAN AG: Tumour suppressor function of the inter-feron-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA (1993) 90:232–236.
   PubMed Web of Science ®Google Scholar
• OSTLUND L, EINHORN S, ROBERT K-H, ET AL.: ChronicB-Iymphocytic leukaemia cells proliferate and differen-tiate following exposure to interferon in vitro. Blood (1986) 67:152–159.
   Google Scholar
• SIDMAN CL, MARSHALL JD, SHULTZ ID, ET AL.: Gamma-interferon is one of several direct B-cell-maturing lym-phokines. Nature (1984) 309:801–804.
   Google Scholar
• CHEN LIC, TOURVIEILLE B, BURNS GF, ET AL.: Interferon: A cytotoxic T-lymphocyte differentiation signal Eur. J. Immunol. (1986) 16:767–770.
   Google Scholar
• GROSSBERG SE, KEAY S: The effects of interferon on3T3-L1 cell differentiation. Ann. NY Acad. Sci. (1980) 350:294–300.
   PubMedGoogle Scholar
• SIEGAL GP, THORGEIRSSON UP, RUSSO RG, WALLACE DM,LIOTTA LA, BERGER SL: Interferon enhancement of the Invasive capacity of Ewing sarcoma cells in vitro. Proc. Natl. Acad. Sci. USA (1982) 79:4064–4068.
   PubMed Web of Science ®Google Scholar
• KURZROCK R, ROHDE MD, QUESADA, ET AL.: Recombi-nant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer pa-tients. J. Exp. Med. (1986) 164:1093–1101.
   Google Scholar
• SCHREIBER RD, PACE JL, RUSSELL SW, ETAL.: Macrophage activating factor produced by a T-cell hybridoma: Physi-cochemical and biosynthetic resemblence to gamma-Interferon.]. Immunol. (1982) 131:826–832.
   Google Scholar
• MURRAY HW, COHN ZA: Macrophage oxygen-depend-ent antimicrobial activity. III. Enhanced oxidative me-tabolism as an expression of macrophage activation.]. Exp. Med. (1980) 152:1596–1609.
   Google Scholar
• PARUSSIA B, DAYTON ET, LAZARUS R, ET AL.: ImmuneInterferon induces the receptor for monomeric IgG1 on human monocytic myeloid cells. J. Exp. Med. (1983) 158:1092–1113.
   Google Scholar
• FELLOUS M, MR U, WALLACH D, ET AL.: Interferon-de-pendent induction of mRNA for the major histocom-patibility antigens in human fibroblasts and lymphoblastold cells, Proc. Natl. Acad. Sci. USA (1982) 79:3082–3086.
   Google Scholar
• SHAW AR, CHAN JK, REID S, ET AL.: HLA-DR synthesisinduction and expression in HIA-DR negative carci-noma cell lines of diverse origins by interferon-gamma but not interferon-beta. J. Natl. Cancer Inst. (1985) 6:1261–1268.
   Google Scholar
• GIACOMINI P, TECCE R, GAMBARI R, ET AL.: Recombinant human IPN-gamma, but not IFN-a or NN-I3, enhances MHC and non-MHC encoded glycoproteins by a protein synthesis dependent mechanism. J. Immunol. (1988) 140:3073–3081.
   Google Scholar
• WELSH RM, KARRE K, HANSON M, ET AL.: Interferon-me-diated protection of normal and tumour target cells against lysis by mouse natural killer cells. J. Immunol. (1981) 1:219–224.
   Google Scholar
• MORIKAWA K, KUBAGAWA H, SUZUKI T, COOPER MD:Recombinant interferon-a, -beta, and -gamma enhance the proliferative response of human B-cells. J. Immunol. (1987) 139:761–766.
   PubMed Web of Science ®Google Scholar
• FLEISHER TA, ATTALAH AM, TOSATO G, ET AL.: Inter-feron-mediated inhibition of human polyclonal immu-noglobulin synthesis. J. Immunol. (1982) 129:1099–1103.
   Google Scholar
• IMAI K, NG A-K, GLASSY MC, ET AL.: Differential effect of interferon on the expression of tumour-associated an-tigens by human melanoma cells. J. Immunol. (1981) 127:505–509.
   Google Scholar
• POWELL J, STONE J, CHAN WG, YANG Z-D, LEATHERBURYA, SELL KW, WIKTO-JEDREJCZAK W, AHMED-ANSARI A: Interferon-gamma-treated K562 target cells distinguish functional NK cells from lympholdne-activated killer (LAK) cells. Cell. Immunol. (1989) 118:250–264.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumour angiogenesis: Therapeutic impli-cations. New Engl. J. Med. (1989) 3201:1211–1212.
   Google Scholar
• ZERIAL A, HOVANESSIAN AG, STEFANOS S: Synergistic activities of type I (a, beta) and type II (gamma) murine interferons. Antiviral Res. (1982) 2: 227–239.
   PubMed Web of Science ®Google Scholar
• TSUJIMOTO M, YIP YK, VILCEK J: Interferon gamma enhances expression of cellular receptors for tumour necrosis factor. J. Immunol. (1986) 136:2441–2444.
   PubMed Web of Science ®Google Scholar
• BILLARD C, SIGAUX F, WIETZERBIN J: IFN-a in vivoenhances tumour necrosis factor receptor levels on hairy cells. J. Immunol. (1990) 145:1713–1718.
   PubMed Web of Science ®Google Scholar
• HESLOP HE, BRENNER MK, GANESHAGURU K, HOFF-BRAND AV: Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br. J. Haematol. (1990) 79:14–16.
   Web of Science ®Google Scholar
• GOODMAN MG: Interaction between cytokines and 8-mercaptoguanosine in humoral immunity: Synergy with interferon. J. Immunol. (1987) 139:142–146.
   PubMed Web of Science ®Google Scholar
• SPIEGEL RJ, JACOBS SL, TRUEHAFT MW: Interferon anti-bodies to interferon alpha 2b: Results of comparative assays and clinical perspective. J. Inteiferon Res. (1989) 9:S17–S24.
   PubMed Web of Science ®Google Scholar
• ROSS C, TINGSGAARD P, JORGENSEN H, VEJLSGAARD GL:Interferon treatment of cutaneous T-cell lymphoma. Eur.J. Haematol. (1993) 51:63–72.
   PubMedGoogle Scholar
• GUTTERmAN jU, HERSH EM: Immunotherapy. In: CancerMedicine. Holland JF, Frei E (Eds.), Lea and Febiger, Phila-delphia (1982):1100–1132.
   Google Scholar
• SLATER LM, WETZEL MW, CESARIO T: Combined inter-feron-anti-metabolite therapy of murine L1210 leukae-mia. Cancer (1981) 48:5–9.
   PubMedGoogle Scholar
• CARMICHAEIJ, FERGUSSON RJ, WOLFF CR, BALKWILL FR, SMYTH F: Augmentation of cytotoxicity of chemother-apy by human a-interferons in human non-small cell lung cancer xenografts. Cancer Res. (1986) 46:4916–4920.
   PubMed Web of Science ®Google Scholar
• GOLDIE JH, COLDMAN AJ: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res. (1984) 44:3643–3653.
   PubMed Web of Science ®Google Scholar
• STEINMANN GG, ROSENKA1MER F, LEITZ G: Clinical ex-periences with interferon-a and interferon-gamma. In: International Review of Experimental Pathology (Volume 34B). Academic Press Inc. (1993):193–207.
   Google Scholar
• WADLER S, SCHWARTZ EL: Antineoplastic activity of thecombination of interferon and cytotoxic agents against experimental and human malignancies. A review. Can-cer Res. (1990) 50:3473–3486.
   PubMed Web of Science ®Google Scholar
• QUESADA JR, REUBEN J, MANNING JT, HERSH EM, GUT-TERMAN JU: Alpha-interferon for induction of remis-sion in hairy cell leukaemia. New Engl. J. Med. (1984) 310:15–18.
   PubMed Web of Science ®Google Scholar
• GOLOMB HM, REFER A, GOLDE DW, OZER H, PORTLOCK C, SILBER R, RAPPEPORT J, RATAIN MJ, THOMPSON J, BONNEM EM, SPIEGEL RJ, TENSEN L, BURKE JS, VARDIMAN JW: Sequential evaluation of alpha-2b interferon treat-ment in 128 patients with hairy cell leukaemia. Semin. OncoL (1987) 14\(Suppl. 2):13–17.
   Google Scholar
• QUESADA JR, HERSH EM, MANNING J, REUBEN J, KEATING M, SCHNIPPER E, ITRI L, GUTTERMAN JU: Treatment of hairy cell leukaemia with recombinant alpha-inter-feron. Blood (1986) 68:493–497.
   PubMed Web of Science ®Google Scholar
• HOFMANN V, FEE B: Long-term treatment of hairy cell leukaemia with interferon alpha-2b. Cancer Treat Rev. (1988) 15(Suppl. A):7.
   Google Scholar
• GOLOMB HM, RATAIN MJ, FEFER A, THOMSON J, GOLDE DW, OZER H, PORTLOCK C, SILBER R, RAPPEPORT J, BONNEM E, SPIEGEL R, TENSEN L, BURKE JS, VARDIMAN JW: Randomised study of the duration of treatment with Interferon alpha-2b in patients with hairy cell leukae-mia. J. Natl. Cancer Inst. (1988) 80:369–373.
   PubMed Web of Science ®Google Scholar
• BERMAN E, HELLER G, KEMPIN S, GEE T, TRAN L, CLARKAON B: Incidence of response and long-term follow-up in patients with hairy cell leukaemia with recombinant alpha-2a. Blood (1990) 75:839–845.
   PubMed Web of Science ®Google Scholar
• HESLOP HE, BRENNER MK, GANESHAGURU K, HOFF-BRAND AV: Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br. J. Haematol. (1991) 79:14–16.
   PubMed Web of Science ®Google Scholar
• KAMPMEIER P, SPIELBERGER R, DICKSTEIN J, MICK R, GOLOMB H, VARDIMAN Increased incidence of sec-ond neoplasms in patients treated with interferon a 2b for hairy cell leukaemia: A clinicopathologic assess-ment. Blood (1994) 83:2931–2938.
   PubMed Web of Science ®Google Scholar
• SAVEN A, PIRO L: NEWCS purine analogues for treatment of hairy cell leukaemia. New Engl.J. Med. (1994) 330:691–697.
   PubMed Web of Science ®Google Scholar
• KANTERJIAN HM, DEISSEROTH A, KURZROCK R, ESTROV Z, TALPAZ M: Chronic myelogenous leukemia: A condse update. Blood (1993) 82:691–703.
   PubMed Web of Science ®Google Scholar
• GREISSHAMMER M, HEHLMANN R, HOCHHAUS A, TALPAZ M, TURA S, STRYCKMANS P, ALLAN NC, TANZER J, KOLB HJ, HEIMPEL H: Interferon in chronic myeloid leukae-mia. A workshop report. Ann. Hematol. (1993) 67:101–106.
   PubMed Web of Science ®Google Scholar
• THE ITALIAN COOPERATIVE STUDY GROUP ON CHRONICMYELOID LEUKAEMIA: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia. New EngL J. Med. (1994) 330:820–825.
   PubMed Web of Science ®Google Scholar
• DOWDING C, GORDON M, GUO A-P, MAISON D, OSTER-HOLZ J, SICZKOWSKI M, GOLDM.AN J: Potential mecha-nisms of action of interferon a in CML. Leuk. Lymphoma (1993) 11:185–191.
   Google Scholar
• SILVER RT: Interferon in the treatment of myeloprolif-erative disease. Semin. Hematol. (1990) 27:6–14.
   PubMed Web of Science ®Google Scholar
• GILES FJ: Maintenance therapy in the myeloprolifera-tive disorders: The current options. Br. J. Haematol. (1991) 79:92–95.
   PubMed Web of Science ®Google Scholar
• SILVER RT: Interferon-a2b: A new treatment for polycthemia vera. Ann. Intern. Med. (1993) 119:1091–1092.
   PubMed Web of Science ®Google Scholar
• QUESADA JR, ALEXANIAN R, HAWKINS M, ET AL.: Treat-ment of multiple myeloma with recombinant a-inter-feron. Blood (1986) 67:275–278.
   Google Scholar
• PAPA G, TUBA S, MANDELL' F, VEGNA ML, DEFAZIO D,MAZZA P, ZDIZANI PL, SIMONI R, DEPITA O, FERRANTI G, GHETTI PL, CRISCUOLO D: Is interferon alpha in cuta-neous T-cell lymphoma a treatment of choice? Br. J. Haematol. (1991) 79:48–51.
   Google Scholar
• DRENO B, ROFERON A: Interferon alpha 2a combined with tigason (etretinate) for treatment of cutaneous T-cell lymphomas. Stem Cells (1993) 11:269–275.
   PubMed Web of Science ®Google Scholar
• ROSEN S, GILYON K, SPRINGER E, ET AL.: Phase 1,11 study of interferon (TEN) alpha-2a combined with pho-totherapy (PUVA) for cutaneous T-cell lymphomas (CTCL). Blood (1988) 72\(Suppl. 1):254a. Abstract.
   Google Scholar
• ROENIGK 1-11-1 JR, KUZEL TM, SKOUTELIS AP, SPRINGER E, YU G, CARO W, GILYON K, VARIAKOJIS D, KAUL K, BUNN PA JR, EVANS L, ROSEN ST: Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol. (1990) 95:198S–205S.
   Google Scholar
• POIESZ B, RUSCETTI F, REITZ M, GRAZDAR A: Detection and isolation of type C retrovirus particles from fresh and cuhurous lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci USA (1980) 77:7415–7419.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P: The role of interferon in the therapy of low grade lymphoma. Leuk. Lymphoma (1993) 10:17–20.
   PubMedGoogle Scholar
• SOLAL-CELIGNY P, LEPAGE E, BROUSSE N, REYES F, HAIOUN C,LEPORRIER M, PEUCHMAUR M, BOSLY A, PAR-LIER Y, BRICE P, COIFFIER B, GISSELBRECIIT C: Recombi- nant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced fol-licular lymphoma. New Engl.J. Med. (1993) 329:1608–1614.
   PubMed Web of Science ®Google Scholar
• LOMS ZIEGLER-HEITBROCK HW, THIEL E: RecombinantIFN-a in lymphomas. J. Invest. Dermatol. (1990) 95:213S–215S.
   Google Scholar
• HORNING SJ, MERIGAN TC, 'CROWN SE, ET AL: Human interferon a in malignant lymphoma and Hodgkin's disease. Cancer (1985) 56:1305–1310.
   PubMed Web of Science ®Google Scholar
• GALE RP, FOON KA: Chronic lymphocytic leukaemia: Recent advances in biology and treatment. Ann. Intern. Med. (1985) 103:101–120.
   PubMed Web of Science ®Google Scholar
• FOON KA, BOTTINO G, ABRAMS PG: Phase II trial ofrecombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukaemia. Am. J. Med. (1985) 78:216–220.
   PubMed Web of Science ®Google Scholar
• BOUSSIOTIS VA, PANGALIS GA: Interferon alpha 2b therapy in untreated early stage b chronic lymphocytic leukaemia patients: One year follow up. Br. J. Haematol. (1991) 79:30–33.
   PubMed Web of Science ®Google Scholar
• PITHA PM: Interferons: Anew class of tumour suppres-sor genes? Cancer Cells (1992) 2:215–216.
   Google Scholar
• WELLS RJ, WECK PK, BAEHNER RL, ETAL.: A phase I study of pharmacokinetics and tolerance. J. Interferon Res. (1988) 8:309–318.
   Google Scholar
• MEYERS JD, FLOURNOY N, SANDERS JE, ET AL.: Prophy-lactic use of human leukocyte interferon after allo-geneic marrow transplantation. Ann. Intern. Med. (1987) 107:809–816.
   Google Scholar
• HAAS OA, MOR W, GADNER H, ET AL.: Treatment of Ph-positive acute lymphoblastic leukaemia with a-in-terferon. Leukaemia (1988) 2:555.
   Google Scholar
• BROWN GP, RUBIN 5, WALKER I, SICHERI D, BELCH A,O'REILLY S, WILSON K, BARR R, JOHNSTON D, JAMES K, ZEE BC, PETER J: Interferon a-2b (IFN) maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma (PCM): Results of a randomised trial. Proc. Am. Soc. Clin. Onc. (1994) 13. Abstract.
   Google Scholar
• MELLSTEDT H, OSTERBORG A, BJORKHOLM J, BJOREMANM, BRENNING G, GAHRTON G, GRIMFORS G, GYELLEN-HAMMAR H, HAST R, JULIUSSON G, JARNMARK M, KILLAN-DER A, KIMBY E, LERNER R, MERK K, OHRLING M, SIMONSSON B, SMEDMYR B, STALFELT AM, STRANDER H, SVEDMYR E, UDEN AM, WADMAN D, OSBY E: Treatment of multiple myeloma with interferon alpha: The Scan-dinavian experience. Br. J. Haematol. (1991)79:21–25.
   PubMed Web of Science ®Google Scholar
• MANELLI F, AVVISATI G, AMADORI S, BOCCADORO M, GERNONE A, LAUTA VM, MARMONT F, PETRUCCI MT, TRIBALTO M, VEGNA ML, DAMMACCO F, PILERI A: Main-tenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New Engl.J. Med. (1990) 322:1430–1434.
   PubMed Web of Science ®Google Scholar